Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1996.14.1.78PMID 8558225
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Age-related structural changes in trabecular and cortical bone: Cellular mechanisms and biomechanical consequences

  2006cited by this paper
• The Royal Marsden Hospital pilot tamoxifen chemoprevention trial

  2004cited by this paper
• Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer.

  1994cited by this paper
• Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study.

  1994cited by this paper
• Recovery of bone density in women who stop using medroxyprogesterone acetate

  1994cited by this paper
• Effect of long‐term tamoxifen therapy on cancellous bone remodeling and structure in women with breast cancer

  1994cited by this paper
• Does long-term administration of tamoxifen affect bone mineral density?

  1993cited by this paper
• The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats.

  1993cited by this paper
• Effect of long term tamoxifen treatment on bone turnover in women with breast cancer.

  1993cited by this paper
• Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women.

  1993cited by this paper
• Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen

  1992cited by this paper
• Estrogens modulate the responsiveness of osteoblast-like cells (ROS 17/2.8) stably transfected with estrogen receptor.

  1992cited by this paper
• Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.

  1992cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  1992cited by this paper
• A potent specific pure antiestrogen with clinical potential.

  1991cited by this paper
• Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy.

  1991cited by this paper
• Functional estrogen receptors in osteoblastic cells demonstrated by transfection with a reporter gene containing an estrogen response element.

  1991cited by this paper
• Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women.

  1990cited by this paper
• Antiestrogen and antiandrogen administration reduce bone mass in the rat.

  1989cited by this paper
• A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer.

  1989cited by this paper
• Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

  1989cited by this paper
• Bone mineral content of women receiving tamoxifen for mastalgia.

  1989cited by this paper
• Effects of tamoxifen on spinal bone density in women with breast cancer.

  1989cited by this paper
• Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women

  1988cited by this paper
• Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years

  1988cited by this paper
• Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats.

  1988cited by this paper
• A feasibility trial of tamoxifen chemoprevention of breast cancer in Great Britain.

  1988cited by this paper
• Evidence of estrogen receptors in normal human osteoblast-like cells.

  1988cited by this paper
• Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells.

  1988cited by this paper
• Evidence of estrogen receptors in normal human osteoblast-like cells

  1988cited by this paper
• Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.

  1987cited by this paper
• Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats

  1987cited by this paper
• Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial.

  1987cited by this paper
• Prolonging tamoxifen therapy for primary breast cancer: findings from the national surgical adjuvant breast and bowel project clinical trial

  1987cited by this paper
• Tamoxifen and contralateral breast cancer.

  1985cited by this paper
• The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer

  1984cited by this paper
• Estrogen and antiestrogen action in reproductive tissues and tumors.

  1979cited by this paper
• A comparative study of antiestrogen action: temporal patterns of antagonism of estrogen stimulated uterine growth and effects on estrogen receptor levels.

  1977cited by this paper
• LONG-TERM PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS BY ŒSTROGEN

  1976cited by this paper
• Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata.

  1976cited by this paper
• Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment.

  1976cited by this paper
• Estrogen receptor-anti-estrogen complex: atypical binding by uterine nuclei and effects on uterine growth.

  1973cited by this paper

• Opportunistic osteoporosis screening on FDG PET/CT scans in breast carcinoma: a comparison with DXA

  2026cites this paper
• Cardiovascular and musculoskeletal health in breast cancer survivors.

  2026cites this paper
• Effects of Anticancer Therapy on Osteoporosis in Breast Cancer Patients: A Nationwide Study Using Data from the National Health Insurance Service-National Health Information Database

  2025cites this paper
• Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti‐Oestrogen Therapy for Breast Cancer

  2025influential citation
• Bone Effects of Anti-Cancer Treatments in 2024

  2025influential citation
• Comparative study on bone mineral density in premenopausal patients with estrogen receptor-positive breast cancer in ASTRRA Study: a 5-year follow-up study

  2025cites this paper
• ERR on the side of caution with endoxifen? - A case series.

  2025cites this paper
• Bone Health Assessment and Management among Survivors of Non-metastatic Breast Cancer: A Narrative Review

  2025cites this paper
• Differential fracture risk in breast cancer patients based on endocrine therapy and age: a nationwide cohort study

  2025influential citation
• A New Model for Bone Health Management in Postmenopausal Early Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy—The Predict & Prevent Project

  2025cites this paper
• Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial

  2025cites this paper
• Impact of Endocrine Therapy on Osteoporosis Risk in Women with Breast Cancer Across Different Hormonal Stages: A Review

  2025cites this paper
• Surgical Management of Adult Spinal Deformity Patients with Osteoporosis

  2024cites this paper
• Bone-Active Drugs in Pre-Menopausal Women with Breast Cancer Under Hormone Deprivation Therapies.

  2024cites this paper
• Gynecologic Care of Black Breast Cancer Survivors

  2024cites this paper
• Mortality associated with osteoporosis and pathological fractures in the United States (1999–2020): a multiple-cause-of-death study

  2024influential citation
• Cancer treatment-induced bone loss

  2024influential citation
• Adverse effects of tamoxifen treatment on bone mineral density in premenopausal patients with breast cancer: a systematic review and meta-analysis

  2024influential citation
• The Role of Rehabilitation in Optimizing Bone Health in Cancer Survivors

  2024cites this paper
• Association between tamoxifen and incidence of osteoporosis in Korean patients with ductal carcinoma in situ

  2024cites this paper
• Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)

  2023cites this paper
• Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer

  2023cites this paper
• Evaluation of Trabecular Microstructure of Cancellous Bone Using Quarter-Detector Computed Tomography

  2023cites this paper
• Relationship between Osteoporosis Patient Outcomes for women with Breast Cancer

  2023cites this paper
• Assessment of the Impact of Anti-Hormonal Treatment on Bone Health in Patients With Breast Cancer Using Machine-Learning Analysis

  2023cites this paper
• Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome.

  2023cites this paper
• Hormonal Therapies in Cancers.

  2023cites this paper
• The beneficial effects of tamoxifen on arteries: a key player for cardiovascular health of breast cancer patient.

  2023cites this paper
• Postnatal Tamoxifen Exposure Induces Long-Lasting Changes to Adipose Tissue in Adult Mice

  2023cites this paper
• Small Change - Big Consequence: The Impact of C15-C16 Double Bond in a D‑ring of Estrone on Estrogen Receptor Activity.

  2023cites this paper
• Effects of adipocyte-specific Dkk1 deletion on bone homeostasis and obesity-induced bone loss in male mice

  2023cites this paper
• Spontaneous Cerebrospinal Fluid Rhinorrhea in a Patient With Breast Cancer

  2023cites this paper
• Breast Cancer Screening and Prevention

  2023cites this paper
• Advances in the Management of Menopausal Symptoms, Fertility Preservation, and Bone Health for Women With Breast Cancer on Endocrine Therapy.

  2023cites this paper
• Retrospective on Structure Activity Relationships with a Focus on Tamoxifen in the Treatment of Breast Cancer

  2023cites this paper
• The effect of breast cancer surgery on spine alignment: Whole-spine radiograph analysis

  2022cites this paper
• Case studies in physiology: Training adaptation in an elite athlete after breast cancer diagnosis.

  2022cites this paper
• Managing Bone Health in Breast Cancer.

  2022cites this paper
• Locally Applied Repositioned Hormones for Oral Bone and Periodontal Tissue Engineering: A Narrative Review

  2022cites this paper
• Atypische femurfracturen: overzicht van de epidemiologie en de behandeling aan de hand van een casus

  2022cites this paper
• Management of Early Stage Breast Cancer: Basics and Controversies

  2021cites this paper
• New insights into the diagnosis and management of bone health in premature ovarian insufficiency

  2021cites this paper
• Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer

  2021cites this paper
• Managing Menopausal Symptoms in Young Women With Breast Cancer: When Medicine Is Not All. The Take Care Project.

  2021cites this paper
• Body Composition Analysis of 10 Years versus 5 Years of Adjuvant Endocrine Therapy in Patients with Nonmetastatic Breast Cancer

  2021cites this paper
• Care for Breast Cancer Survivors.

  2021cites this paper
• Estrogen receptor alpha in the brain mediates tamoxifen-induced changes in physiology in mice

  2021cites this paper
• Impact of breast cancer and its treatment on bone loss and fracture risk—pathophysiology and management

  2021cites this paper
• Perils of Prolonged Ovarian Suppression and Hypoestrogenism in the Treatment of Breast Cancer: Is the Risk of Treatment Worse than the Risk of Recurrence?

  2021cites this paper
• Adherence to bone health guidelines in patients with hormone receptor-positive early breast cancer: Status and clinical impact in a Swiss cohort experience

  2021cites this paper
• Osteoporosis Therapy: Mechanistic Antiresorptives

  2021cites this paper
• Selective estrogen receptor modulators and bone health

  2021cites this paper
• Bone-modifying Agents (BMAs) in Breast Cancer.

  2021cites this paper
• Selective Estrogen Receptor Modulators: A Potential Option For Non-Binary Gender-Affirming Hormonal Care?

  2021cites this paper
• Breast cancer therapy and bone

  2021cites this paper
• Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer

  2021cites this paper
• Osteoporosis in premenopausal women, pregnancy, and lactation

  2021cites this paper
• Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease

  2021cites this paper
• Adjuvant Endocrine Therapy in Early Breast Cancer

  2020cites this paper
• Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy

  2020cites this paper
• Management of Early Menopause/Premature Ovarian Insufficiency in Women with or at High Risk of Breast Cancer

  2020cites this paper
• Musculoskeletal Health in Premature Ovarian Insufficiency. Part Two: Bone

  2020cites this paper
• Osteoporosis in Premenopausal Women

  2020cites this paper
• Hypothalamic estrogen receptor alpha mediates key side effects of tamoxifen therapy in mice

  2020cites this paper
• Endocrine Therapy-related Endocrinopathies-Biology, Prevalence and Implications for the Management of Breast Cancer.

  2020cites this paper
• 50th ANNIVERSARY OF THE FIRST CLINICAL TRIAL WITH ICI 46,474 (TAMOXIFEN): THEN WHAT HAPPENED?

  2020cites this paper
• Adjuvant Surgical Oophorectomy Plus Tamoxifen: New Efficacy and Secondary Effects Data

  2020cites this paper
• BCTT_A_266314 123..130

  2020cites this paper
• Evaluation of periodontal health in breast cancer patients undergoing tamoxifen or aromatase inhibitors drugs therapy: A cross-sectional study.

  2020cites this paper
• Breast cancer survivorship.

  2020cites this paper
• Effect of Tamoxifen on the Risk of Osteoporosis and Osteoporotic Fracture in Younger Breast Cancer Survivors: A Nationwide Study

  2020cites this paper
• Management of osteoporosis in women with breast cancer

  2020cites this paper
• Challenges in preventing bone loss induced by aromatase inhibitors.

  2020cites this paper
• Risk of osteoporosis and fracture in long-term breast cancer survivors

  2020cites this paper
• Bone Health in Premenopausal Chinese Patients after Adjuvant Chemotherapy for Early Breast Cancer

  2020cites this paper
• New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight.

  2020cites this paper
• Fulvestrant in the treatment of luminal metastatic breast cancer: the balance of effectiveness and safety

  2020cites this paper
• Spontaneous Rib Fractures After Breast Cancer Treatment Based on Bone Scans: Comparison Of Conventional Versus Hypofractionated Radiotherapy.

  2020cites this paper
• Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments

  2020cites this paper
• New Insights Into Implementation of Mesenchymal Stem Cells in Cancer Therapy: Prospects for Anti-angiogenesis Treatment

  2019cites this paper
• Recommandations françaises de stratégies thérapeutiques pour la prévention et le traitement de l’ostéoporose induite par les traitements adjuvants du cancer du sein

  2019cites this paper
• Polypoid endometriosis: a mimic of malignancy

  2019cites this paper
• The pharmacology of selective estrogen receptor modulators: past and present

  2019cites this paper
• Bone Health in Patients with Breast Cancer

  2019cites this paper
• Incidence and location of bone metastases in breast cancer

  2019cites this paper
• Increased NF-κB Activity in Osteoprogenitor-Lineage Cells Impairs the Balance of Bone Versus Fat in the Marrow of Skeletally Mature Mice

  2019cites this paper
• French Recommendations on Strategies for Preventing and Treating Osteoporosis Induced by Adjuvant Breast Cancer Therapies.

  2019cites this paper
• Les modulateurs sélectifs des récepteurs aux œstrogènes : à propos de deux exemples

  2019cites this paper
• BREAST CANCER THERAPY

  2019cites this paper
• Estrogen-mediated protection against coronary heart disease: The role of the Notch pathway.

  2019cites this paper
• The effects of adjuvant endocrine therapy on bone health in women with breast cancer.

  2019cites this paper
• Bone health in women with breast cancer

  2019cites this paper
• Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators

  2019cites this paper
• The Principles behind Targeted Therapy for Cancer Treatment

  2019cites this paper
• Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression.

  2019cites this paper
• Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant)

  2018cites this paper
• Long-Term High-Dose Resveratrol Supplementation Reduces Bone Mass and Fracture Strength in Rats

  2018cites this paper
• Nano Packaged Tamoxifen and Curcumin; Effective Formulation against Sensitive and Resistant MCF-7 Cells

  2018cites this paper
• Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer

  2018cites this paper
• Bayesian synthesis using prior information on fracture risk from randomized trials to analyze post-market data.

  2018cites this paper